Abstract
Objective To investigate the relationship between the long noncoding RNA (lncRNA) Prostate cancer-associated transcription factors 14 (PCAT14) and the clinical characteristics of prostate cancer and immune cell infiltration. Methods The relationship between PCAT14 expression and the clinicopathological characteristics of prostate cancer was analyzed based on The Cancer Genome Atlas (TCGA) database. Receiver operating characteristic (ROC) curves were used to evaluate the value of PCAT14 as a diagnostic marker for prostate cancer. The relationship between PCAT14 and immune cell infiltration was analyzed to explore the effect of PCAT14 on the immune-related functions of prostate cancer. Results The ROC curve showed that PCAT14 had a significant diagnostic ability (area under curve = 0.818) for prostate cancer. A reduced expression of PCAT14 in prostate cancer was related to T stage, N stage, primary therapy outcome, residual tumor, Gleason score, and age. The expression of PCAT14 was independently associated with the progression-free interval in prostate cancer patients. The infiltration of immune cells in prostate cancer showed a significant negative correlation between the expression of PCAT14 and plasmacytoid dendritic cells, activated dendritic cells, regulatory T cells, and neutrophils. Conclusions PCAT14 is highly expressed in prostate cancer and is expected to be a diagnostic marker. PCAT14 might promote the development of prostate cancer through chemokines, antimicrobials, and cytokines that affect the infiltration of immune cells.
Highlights
Prostate cancer is the second leading cause of cancer-related deaths in men, according to the 2018 global cancer incidence and mortality statistics [1]
We analyzed the expression of Prostate cancer-associated transcription factors 14 (PCAT14) in 499 prostate cancer samples and 52 adjacent normal tissue samples, and the results showed that PCAT14 was highly expressed in prostate cancer tissues (Figure 1(a))
The results showed that PCAT14 expression was negatively correlated with the infiltration of plasmacytoid dendritic cells, activated dendritic cells, regulatory T cells (Tregs), and neutrophils (Figures 3 and 4)
Summary
Prostate cancer is the second leading cause of cancer-related deaths in men, according to the 2018 global cancer incidence and mortality statistics [1]. Prostate-specific antigen (PSA) is used as the main marker for prostate cancer screening, diagnosis, and prognosis. PSA alone as a single marker still has great limitations in diagnosing and determining prostate cancer prognosis. It is necessary to continue the search for more potentially effective markers for the diagnosis and prognosis of prostate cancer. The treatment of prostate cancer has made some progress, but it is still not satisfactory. Further studies on the pathogenesis of prostate cancer are still needed to provide more clues for the treatment of prostate cancer
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
